Outrage at Cancer Drugs Fund casualty list
This article was originally published in Scrip
Executive Summary
It looks like Sanofi, Novartis and Eisai are the first companies to have their drugs dropped from England's Cancer Drugs Fund (CDF) under a controversial new review process which industry has described has "devastating" and "appalling".